0001493152-26-009686
SEC filingEvofem Biosciences, Inc. reported net income of $391,000 for fiscal year 2025, marking a significant improvement from prior periods. The company generated $20.2 million in net product sales with a gross profit of $15.6 million, resulting in a gross margin of 77.2%. Operating income was $3.4 million, driven by a $1.9 million gain on change in accounting estimates on contingent royalty liability. The company ended the year with $20.3 million in total assets but faces substantial liabilities of $89.7 million, resulting in a stockholders' deficit of $74.3 million. Cash flow from operations was negative $2.0 million, though financing activities provided $1.9 million in cash. The company's liquidity position remains constrained with only $578,000 in restricted cash and cash equivalents against $84.8 million in current liabilities.
Evofem Biosciences reported net income of $391,000 for fiscal year 2025, a significant turnaround from prior periods of losses. The company achieved $20.2 million in net product sales with cost of goods sold of $4.6 million, resulting in gross profit of $15.6 million. Operating income was $3.4 million, which included a $1.9 million gain on change in accounting estimates on contingent royalty liability. Total operating expenses were $16.8 million, comprising selling and marketing expenses of $9.7 million, general and administrative expenses of $7.4 million, research and development net expense of $3.4 million, and amortization of intangible asset of $499,000. Other expenses totaled $3.0 million, primarily from loss on issuance of financial instruments of $3.3 million, partially offset by gain on debt extinguishment of $977,000.
The company's revenue consists entirely of product sales, which totaled $20.2 million for fiscal year 2025. No segment breakdown or geographic revenue mix is disclosed in the provided data. The revenue appears to be generated from the company's primary product offerings, though specific product-level details are not provided. The $20.2 million in net product sales represents the company's core operating revenue stream, with no other revenue sources mentioned in the income statement data.
The company achieved a gross margin of 77.2% based on $15.6 million gross profit from $20.2 million in net product sales. Operating margin was 16.8% with operating income of $3.4 million. The profitability was significantly impacted by the $1.9 million gain on change in accounting estimates on contingent royalty liability, which contributed substantially to the operating income. Without this gain, operating income would have been $1.5 million. The cost structure shows selling and marketing expenses of $9.7 million (48.0% of revenue) and general and administrative expenses of $7.4 million (36.6% of revenue), indicating high operating expense ratios relative to revenue.
Operating cash flow was negative $2.0 million despite net income of $391,000, primarily due to non-cash adjustments including $5.6 million gain on accounts payable and accrued expenses settlements, $2.4 million noncash interest expense, and $1.9 million gain on change in accounting estimates. The balance sheet shows total assets of $20.3 million, including $15.3 million in current assets with $12.5 million in trade accounts receivable. Total liabilities are $89.7 million, including $54.2 million in convertible notes and $13.2 million in accounts payable. Stockholders' deficit is $74.3 million with accumulated deficit of $897.4 million. Liquidity is constrained with only $578,000 in restricted cash and cash equivalents against $84.8 million in current liabilities.
No forward-looking guidance, management commentary, or specific strategic priorities are provided in the financial data. The filing does not include risk factor disclosures or management discussion and analysis sections that would typically contain outlook information. The company's financial position shows significant challenges with high debt levels, negative equity position, and constrained liquidity that will likely require additional financing or restructuring to sustain operations.